Findings from Heinrich-Heine-University Yields New Findings on Healthcare Economics (Tiered co-payments, pricing, and demand in reference price…
Findings from Heinrich-Heine-University Yields New Findings on Healthcare Economics (Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals)
By a
Our news journalists obtained a quote from the research from Heinrich-Heine-University, "First, using a difference-in-differences estimation strategy, we find that the new policy decreases prices by 5 percent for generics and increases prices by 4 percent for brand-name drugs in the German reference price market. Second, estimating a nested-logit demand model, we show that consumers appreciate co-payment exempt drugs and calculate lower price elasticities for brand-name drugs than for generics."
According to the news editors, the research concluded: "This explains the different price responses of brand-name and generic drugs and shows that price-related co-payment tiers are an effective tool to steer demand to low-priced drugs."
For more information on this research see: Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals.
Our news journalists report that additional information may be obtained by contacting A. Herr, Heinrich Heine Univ, DICE,
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jhealeco.2017.08.008. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
ACLU sues Kansas over Hep C drug denials for Medicaid patients
American Equity Reports Fourth Quarter and Full Year 2017 Results
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News